Pfizer Announces Top-Line Results Of Third Phase 3 Clinical Trial Of Tofacitinib In Patients With Active Rheumatoid Arthritis

Pfizer Inc. PFE announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor. ORAL Scan is an ongoing two-year study in patients with moderate-to-severe active rheumatoid arthritis who had an inadequate response to methotrexate and were randomized to receive tofacitinib 5 or 10 mg BID or placebo added to background MTX. The data reported are from a planned analysis at one year.